News

Aural Analytics’ speech-based digital technology will be used to measure changes in speech in people with amyotrophic lateral sclerosis (ALS) as endpoints for the HEALEY ALS Platform Trial, which is evaluating multiple potential ALS treatments…

AC Immune is planning to advance its investigational anti-TDP-43 antibody into clinical testing for neurodegenerative diseases, like amyotrophic lateral sclerosis (ALS), in which TPD-43 protein aggregates play a major role in brain damage. The company announced the start of preclinical studies into this first-in-class antibody. This work will…

For three weeks during Lou Gehrig’s final season, the baseball legend appeared to shake off his symptoms of amyotrophic lateral sclerosis (ALS) and regain his flagging prowess. Richard Bedlack, MD, PhD, founder and director of Duke University’s ALS clinic, and baseball author Dan Joseph, provide an…

The first platform trial for amyotrophic lateral sclerosis (ALS), designed to assess multiple treatment candidates simultaneously with a goal of accelerating the development of ALS therapies, has enrolled its first patients. The HEALEY ALS Platform Trial (NCT04297683) will start by evaluating UCB’s…

Kadimastem’s cell therapy candidate, AstroRx, significantly lowers the rate of disease progression in people with amyotrophic lateral sclerosis (ALS) for at least three months after treatment, updated findings from the company’s Phase 1/2 clinical trial show. The company already had reported promising…

The clear, colorless liquid that fills and surrounds the brain and spinal cord in people with amyotrophic lateral sclerosis (ALS) seems to induce early neurodegeneration events in healthy motor neurons, a study has found. When motor neurons were continuously cultured with cerebrospinal fluid  from ALS patients, cells showed…

Stem cells collected from a patient’s bone marrow and infused into the spinal fluid safely improved speaking abilities after 28 days for most of the 12 adults with amyotrophic lateral sclerosis (ALS) evaluated in a small study. Its researchers recommend further…

The gut microbiome in people with amyotrophic lateral sclerosis (ALS) is altered compared to healthy people, which includes an imbalance in potentially protective microbial groups and others with pro-inflammatory activity, a study found.  Also, while taking probiotic supplements over six months…

Orion Corporation’s oral therapy levosimendan (ODM-109) failed to preserve lung function and overall functionality in people with amyotrophic lateral sclerosis (ALS), data from the Phase 3 REFALS clinical trial show. “We would like to express our warmest thanks to the patients, carers and investigators for participating in the REFALS…

Measurements taken of muscle using ultrasound could be useful in diagnosing or managing amyotrophic lateral sclerosis (ALS), a small study suggests. The study, “Application of Muscle Ultrasound for the evaluation of Patients with Amyotrophic Lateral Sclerosis: An observational Cross‐Sectional Study,” was published in Muscle & Nerve.